After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Ginkgo Bioworks Holdings Inc is listed on the NYSE as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Ginkgo Bioworks Holdings Inc is $2.28B. A total of 15.65 million shares were traded on the day, compared to an average of 22.37M shares.
In the most recent transaction, Dmytruk Mark E. sold 51,169 shares of DNA for 1.05 per share on Apr 02 ’24. After the transaction, the insider now owns 865,079 company shares. In a previous transaction on Mar 04 ’24, Dmytruk Mark E. sold 38,826 shares at 1.26 per share. DNA shares that the insider owns now total 808,125.
Among the insiders who sold shares, Dmytruk Mark E. disposed of 39,569 shares on Feb 02 ’24 at a per-share price of $1.21. This resulted in the insider holding 761,737 shares of DNA after the transaction. In another insider transaction, Kelly Jason R sold 100,000 shares at $1.55 per share on Jan 04 ’24. Company shares held by the insider now total 3,894,680.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, DNA has a high of $2.55 and a low of $1.03.
As of this writing, DNA has an earnings estimate of -$0.08 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.08 per share and a lower estimate of -$0.1. The company reported an EPS of -$0.16 in the last quarter, which was -77.80% lower than expectations of -$0.09.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $0.58, while its Total Shareholder’s Equity was $1.57B.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 2.86.
